M1-like TAMs are required for the efficacy of PD-L1/PD-1 blockades in gastric cancer

The efficacy of PD-1/PD-L1 blockades is heterogeneous in different molecular subtypes of gastric cancer (GC). In this study, we analyzed relevant clinical trials to identify the molecular subtypes associated with the efficacy of PD-1/PD-L1 blockades, and public datasets, patient samples, and GC cell...

Celý popis

Uloženo v:

Podrobná bibliografie
Vydáno v:	Oncoimmunology Ročník 10; číslo 1; s. 1862520
Hlavní autoři:	Zhao, Rui, Wan, Qianyi, Wang, Yong, Wu, Yutao, Xiao, Shuomeng, Li, Qiqi, Shen, Xiaoding, Zhuang, Wen, Zhou, Yong, Xia, Lin, Song, Yinghan, Chen, Yi, Yang, Hanshuo, Wu, Xiaoting
Médium:	Journal Article
Jazyk:	angličtina
Vydáno:	United States Taylor & Francis 01.01.2021 Taylor & Francis Group
Témata:	gastric cancer Original Research PD-L1/PD-1 blockades Tumor-associated macrophages gastric cancer PD-L1/PD-1 blockades Tumor-associated macrophages
ISSN:	2162-402X, 2162-4011, 2162-402X
On-line přístup:	Získat plný text
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!

Abstract	The efficacy of PD-1/PD-L1 blockades is heterogeneous in different molecular subtypes of gastric cancer (GC). In this study, we analyzed relevant clinical trials to identify the molecular subtypes associated with the efficacy of PD-1/PD-L1 blockades, and public datasets, patient samples, and GC cell lines were used for investigating potential mechanisms. We found that GC with EBV-positive, MSI-H/dMMR, TMB-H or PIK3CA mutant subtype had enhanced efficacy of PD-L1/PD-1 blockades. Also, differentially expressed genes of these molecular subtypes shared the same gene signature and functional annotations related to immunity. Meanwhile, CIBERSORT identified that the overlapping landscapes of tumor-infiltrating immune cells in the four molecular subtypes were mainly M1-like macrophages (M1). The relationships between M1 and clinical characteristics, M1, and gene signatures associated with PD-1/PD-L1 blockades also revealed that M1 was associated with improved prognosis and required for the efficacy of PD-L1/PD-1 blockades in GC. We identified that tumor-infiltrating CD68 + CD163 − macrophages could represent M1 calculated by CIBERSORT in clinical application, and CXCL9, 10, 11/CXCR3 axis was involved in the mechanism of CD68 + CD163 − macrophages in the enhanced efficacy of PD-L1/PD-1 blockades. In conclusion, CD68 + CD163 − macrophages are required for the efficacy of PD-L1/PD-1 blockades and expand the applicable candidates in GC patients without the molecular subtypes.
AbstractList	The efficacy of PD-1/PD-L1 blockades is heterogeneous in different molecular subtypes of gastric cancer (GC). In this study, we analyzed relevant clinical trials to identify the molecular subtypes associated with the efficacy of PD-1/PD-L1 blockades, and public datasets, patient samples, and GC cell lines were used for investigating potential mechanisms. We found that GC with EBV-positive, MSI-H/dMMR, TMB-H or PIK3CA mutant subtype had enhanced efficacy of PD-L1/PD-1 blockades. Also, differentially expressed genes of these molecular subtypes shared the same gene signature and functional annotations related to immunity. Meanwhile, CIBERSORT identified that the overlapping landscapes of tumor-infiltrating immune cells in the four molecular subtypes were mainly M1-like macrophages (M1). The relationships between M1 and clinical characteristics, M1, and gene signatures associated with PD-1/PD-L1 blockades also revealed that M1 was associated with improved prognosis and required for the efficacy of PD-L1/PD-1 blockades in GC. We identified that tumor-infiltrating CD68+CD163− macrophages could represent M1 calculated by CIBERSORT in clinical application, and CXCL9, 10, 11/CXCR3 axis was involved in the mechanism of CD68+CD163− macrophages in the enhanced efficacy of PD-L1/PD-1 blockades. In conclusion, CD68+CD163− macrophages are required for the efficacy of PD-L1/PD-1 blockades and expand the applicable candidates in GC patients without the molecular subtypes. The efficacy of PD-1/PD-L1 blockades is heterogeneous in different molecular subtypes of gastric cancer (GC). In this study, we analyzed relevant clinical trials to identify the molecular subtypes associated with the efficacy of PD-1/PD-L1 blockades, and public datasets, patient samples, and GC cell lines were used for investigating potential mechanisms. We found that GC with EBV-positive, MSI-H/dMMR, TMB-H or PIK3CA mutant subtype had enhanced efficacy of PD-L1/PD-1 blockades. Also, differentially expressed genes of these molecular subtypes shared the same gene signature and functional annotations related to immunity. Meanwhile, CIBERSORT identified that the overlapping landscapes of tumor-infiltrating immune cells in the four molecular subtypes were mainly M1-like macrophages (M1). The relationships between M1 and clinical characteristics, M1, and gene signatures associated with PD-1/PD-L1 blockades also revealed that M1 was associated with improved prognosis and required for the efficacy of PD-L1/PD-1 blockades in GC. We identified that tumor-infiltrating CD68 + CD163 − macrophages could represent M1 calculated by CIBERSORT in clinical application, and CXCL9, 10, 11/CXCR3 axis was involved in the mechanism of CD68 + CD163 − macrophages in the enhanced efficacy of PD-L1/PD-1 blockades. In conclusion, CD68 + CD163 − macrophages are required for the efficacy of PD-L1/PD-1 blockades and expand the applicable candidates in GC patients without the molecular subtypes. The efficacy of PD-1/PD-L1 blockades is heterogeneous in different molecular subtypes of gastric cancer (GC). In this study, we analyzed relevant clinical trials to identify the molecular subtypes associated with the efficacy of PD-1/PD-L1 blockades, and public datasets, patient samples, and GC cell lines were used for investigating potential mechanisms. We found that GC with EBV-positive, MSI-H/dMMR, TMB-H or PIK3CA mutant subtype had enhanced efficacy of PD-L1/PD-1 blockades. Also, differentially expressed genes of these molecular subtypes shared the same gene signature and functional annotations related to immunity. Meanwhile, CIBERSORT identified that the overlapping landscapes of tumor-infiltrating immune cells in the four molecular subtypes were mainly M1-like macrophages (M1). The relationships between M1 and clinical characteristics, M1, and gene signatures associated with PD-1/PD-L1 blockades also revealed that M1 was associated with improved prognosis and required for the efficacy of PD-L1/PD-1 blockades in GC. We identified that tumor-infiltrating CD68+CD163- macrophages could represent M1 calculated by CIBERSORT in clinical application, and CXCL9, 10, 11/CXCR3 axis was involved in the mechanism of CD68+CD163- macrophages in the enhanced efficacy of PD-L1/PD-1 blockades. In conclusion, CD68+CD163- macrophages are required for the efficacy of PD-L1/PD-1 blockades and expand the applicable candidates in GC patients without the molecular subtypes.The efficacy of PD-1/PD-L1 blockades is heterogeneous in different molecular subtypes of gastric cancer (GC). In this study, we analyzed relevant clinical trials to identify the molecular subtypes associated with the efficacy of PD-1/PD-L1 blockades, and public datasets, patient samples, and GC cell lines were used for investigating potential mechanisms. We found that GC with EBV-positive, MSI-H/dMMR, TMB-H or PIK3CA mutant subtype had enhanced efficacy of PD-L1/PD-1 blockades. Also, differentially expressed genes of these molecular subtypes shared the same gene signature and functional annotations related to immunity. Meanwhile, CIBERSORT identified that the overlapping landscapes of tumor-infiltrating immune cells in the four molecular subtypes were mainly M1-like macrophages (M1). The relationships between M1 and clinical characteristics, M1, and gene signatures associated with PD-1/PD-L1 blockades also revealed that M1 was associated with improved prognosis and required for the efficacy of PD-L1/PD-1 blockades in GC. We identified that tumor-infiltrating CD68+CD163- macrophages could represent M1 calculated by CIBERSORT in clinical application, and CXCL9, 10, 11/CXCR3 axis was involved in the mechanism of CD68+CD163- macrophages in the enhanced efficacy of PD-L1/PD-1 blockades. In conclusion, CD68+CD163- macrophages are required for the efficacy of PD-L1/PD-1 blockades and expand the applicable candidates in GC patients without the molecular subtypes. The efficacy of PD-1/PD-L1 blockades is heterogeneous in different molecular subtypes of gastric cancer (GC). In this study, we analyzed relevant clinical trials to identify the molecular subtypes associated with the efficacy of PD-1/PD-L1 blockades, and public datasets, patient samples, and GC cell lines were used for investigating potential mechanisms. We found that GC with EBV-positive, MSI-H/dMMR, TMB-H or PIK3CA mutant subtype had enhanced efficacy of PD-L1/PD-1 blockades. Also, differentially expressed genes of these molecular subtypes shared the same gene signature and functional annotations related to immunity. Meanwhile, CIBERSORT identified that the overlapping landscapes of tumor-infiltrating immune cells in the four molecular subtypes were mainly M1-like macrophages (M1). The relationships between M1 and clinical characteristics, M1, and gene signatures associated with PD-1/PD-L1 blockades also revealed that M1 was associated with improved prognosis and required for the efficacy of PD-L1/PD-1 blockades in GC. We identified that tumor-infiltrating CD68 CD163 macrophages could represent M1 calculated by CIBERSORT in clinical application, and CXCL9, 10, 11/CXCR3 axis was involved in the mechanism of CD68 CD163 macrophages in the enhanced efficacy of PD-L1/PD-1 blockades. In conclusion, CD68 CD163 macrophages are required for the efficacy of PD-L1/PD-1 blockades and expand the applicable candidates in GC patients without the molecular subtypes.
Author	Chen, Yi Wu, Yutao Li, Qiqi Zhou, Yong Wang, Yong Yang, Hanshuo Wan, Qianyi Xiao, Shuomeng Song, Yinghan Xia, Lin Zhuang, Wen Zhao, Rui Shen, Xiaoding Wu, Xiaoting
Author_xml	– sequence: 1 givenname: Rui surname: Zhao fullname: Zhao, Rui organization: West China Hospital, Sichuan University – sequence: 2 givenname: Qianyi surname: Wan fullname: Wan, Qianyi organization: West China Hospital, Sichuan University – sequence: 3 givenname: Yong surname: Wang fullname: Wang, Yong organization: West China Hospital, Sichuan University – sequence: 4 givenname: Yutao surname: Wu fullname: Wu, Yutao organization: Sichuan University – sequence: 5 givenname: Shuomeng surname: Xiao fullname: Xiao, Shuomeng organization: West China Hospital, Sichuan University – sequence: 6 givenname: Qiqi surname: Li fullname: Li, Qiqi organization: Sichuan University – sequence: 7 givenname: Xiaoding surname: Shen fullname: Shen, Xiaoding organization: West China Hospital, Sichuan University – sequence: 8 givenname: Wen surname: Zhuang fullname: Zhuang, Wen organization: West China Hospital, Sichuan University – sequence: 9 givenname: Yong surname: Zhou fullname: Zhou, Yong organization: West China Hospital, Sichuan University – sequence: 10 givenname: Lin surname: Xia fullname: Xia, Lin organization: West China Hospital, Sichuan University – sequence: 11 givenname: Yinghan surname: Song fullname: Song, Yinghan organization: West China Hospital, Sichuan University – sequence: 12 givenname: Yi surname: Chen fullname: Chen, Yi organization: West China Hospital, Sichuan University – sequence: 13 givenname: Hanshuo surname: Yang fullname: Yang, Hanshuo email: yhansh@126.com organization: Sichuan University – sequence: 14 givenname: Xiaoting orcidid: 0000-0002-3996-868X surname: Wu fullname: Wu, Xiaoting email: wxt1@medmail.com.cn organization: West China Hospital, Sichuan University
BackLink	https://www.ncbi.nlm.nih.gov/pubmed/33457080$$D View this record in MEDLINE/PubMed
BookMark	eNqFkkFv1DAQhS1UREvpTwD5yCWtndhOIiREVUpbaSs4LBI3a-KMt269cWtnqfbf47C7qOUAtmRb43nfO8x7TfaGMCAhbzk75qxhJyVXpWDlj-OSlbnUqFKW7AU5mOrF9LH35L1PjlK6ZXkpJlXVviL7VSVknUEHZH7NC-_ukM5PrxOFiDTiw8pF7KkNkY43SNFaZ8CsabD02-dixk_yyWnng7mDHhN1A11AGqMz1MBgML4hLy34hEfb-5B8_3I-P7ssZl8vrs5OZ4WRlRiLrpMooas6ppRtbdtwUNZYxTuorYUekDMletGCAtEqwVoQgtdgDG-s6rE6JFcbbh_gVt9Ht4S41gGc_l0IcaEhjs541MxWmHeD2Jei7qBF3rCuVDLbt9DKzPq4Yd2vuiX2Bocxgn8Gff4zuBu9CD91XTe8liID3m8BMTysMI166ZJB72HAsEo62zZ1zSvOc-u7p15_THZjyQ0fNg0mhpQiWm3cCKMLk7XzmjM95UDvcqCnHOhtDrJa_qXeGfxP92mjc0Oe_RIeQ_S9HmHtQ7QxT9YlXf0b8QuCs8hA
CitedBy_id	crossref_primary_10_1186_s13045_023_01498_2 crossref_primary_10_1016_j_bbadis_2023_166881 crossref_primary_10_3390_ijms252111735 crossref_primary_10_1007_s10120_024_01523_4 crossref_primary_10_1007_s10238_023_01059_4 crossref_primary_10_1007_s13346_024_01595_w crossref_primary_10_1186_s40659_025_00597_3 crossref_primary_10_1016_j_ejphar_2025_177268 crossref_primary_10_3390_ijms252413413 crossref_primary_10_3389_fimmu_2022_1043517 crossref_primary_10_3389_fphar_2025_1611234 crossref_primary_10_1158_2326_6066_CIR_22_0218 crossref_primary_10_3390_cells10112988 crossref_primary_10_3389_fonc_2021_710286 crossref_primary_10_3390_cancers13205189 crossref_primary_10_1016_j_ctrv_2024_102737 crossref_primary_10_3389_fonc_2021_737061 crossref_primary_10_1016_j_cytogfr_2022_07_004 crossref_primary_10_1155_2022_2218140 crossref_primary_10_1039_D1BM01053K crossref_primary_10_1155_2022_8965903 crossref_primary_10_2174_1381612829666230901143203 crossref_primary_10_3389_fonc_2022_984560 crossref_primary_10_3389_fimmu_2024_1438859 crossref_primary_10_1186_s12951_023_02240_3 crossref_primary_10_3389_fimmu_2022_1016817 crossref_primary_10_3390_cancers13184712 crossref_primary_10_1080_2162402X_2023_2230669 crossref_primary_10_1007_s00262_021_02933_4 crossref_primary_10_3389_fimmu_2021_690869 crossref_primary_10_3389_fgene_2024_1421573 crossref_primary_10_1016_j_gene_2022_146962 crossref_primary_10_1016_j_tranon_2024_102181
Cites_doi	10.1093/annonc/mdz197 10.1186/s12885-018-4384-8 10.1038/s41568-019-0235-4 10.1016/j.immuni.2020.06.016 10.1200/JCO.2017.76.6212 10.1158/2326-6066.CIR-17-0746 10.1038/s41577-019-0127-6 10.1007/s10120-017-0760-3 10.1007/s10120-020-01090-4 10.1016/j.ccell.2018.02.005 10.1007/s10120-018-0903-1 10.1093/jnci/djaa051 10.1038/s41591-018-0101-z 10.1038/s41467-018-03121-2 10.1038/nrclinonc.2016.217 10.3322/caac.21492 10.1080/2162402X.2019.1581547 10.1016/j.cmet.2019.06.001 10.1038/s41467-019-11788-4 10.1097/SLA.0000000000004037 10.1136/gutjnl-2015-310839 10.1016/j.cell.2010.03.014 10.2147/OTT.S246412 10.1186/s40425-019-0514-3 10.1016/j.ctrv.2017.11.007 10.1186/s13045-017-0408-0 10.1016/j.it.2019.02.003 10.1146/annurev-pathmechdis-012418-012718 10.1016/S1470-2045(16)00175-3 10.1093/annonc/mdy540 10.1007/s10120-019-00999-9 10.1038/nrd.2018.169 10.1038/nature13480 10.1001/jamaoncol.2018.0013 10.1111/cpr.12571 10.1158/2326-6066.CIR-19-0826 10.1016/j.ctrv.2020.102015 10.1038/s41467-017-01572-7 10.1016/j.immuni.2019.04.010 10.1016/j.ccell.2018.03.008 10.1126/scitranslmed.3003689 10.1172/JCI91190 10.1007/s40265-020-01272-5 10.1038/ncomms8458 10.1038/s41586-020-2746-2
ContentType	Journal Article
Copyright	2020 The Author(s). Published with license by Taylor & Francis Group, LLC. 2020 2020 The Author(s). Published with license by Taylor & Francis Group, LLC. 2020 The Author(s). Published with license by Taylor & Francis Group, LLC. 2020 The Author(s)
Copyright_xml	– notice: 2020 The Author(s). Published with license by Taylor & Francis Group, LLC. 2020 – notice: 2020 The Author(s). Published with license by Taylor & Francis Group, LLC. – notice: 2020 The Author(s). Published with license by Taylor & Francis Group, LLC. 2020 The Author(s)
DBID	0YH AAYXX CITATION NPM 7X8 5PM DOA
DOI	10.1080/2162402X.2020.1862520
DatabaseName	Taylor & Francis Open Access CrossRef PubMed MEDLINE - Academic PubMed Central (Full Participant titles) DOAJ Directory of Open Access Journals
DatabaseTitle	CrossRef PubMed MEDLINE - Academic
DatabaseTitleList	MEDLINE - Academic PubMed
Database_xml	– sequence: 1 dbid: DOA name: DOAJ Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 2 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 3 dbid: 0YH name: Taylor & Francis Open Access url: https://www.tandfonline.com sourceTypes: Publisher – sequence: 4 dbid: 7X8 name: MEDLINE - Academic url: https://search.proquest.com/medline sourceTypes: Aggregation Database
DeliveryMethod	fulltext_linktorsrc
Discipline	Biology
DocumentTitleAlternate	R. ZHAO ET AL
EISSN	2162-402X
ExternalDocumentID	oai_doaj_org_article_0f3e3e38eed247ba9e180b265b3b9a95 PMC7781754 33457080 10_1080_2162402X_2020_1862520 1862520
Genre	Research Article Journal Article
GrantInformation_xml	– fundername: Sichuan Province Science and Technology – fundername: Sichuan Province Science and Technology Support Project grantid: 2012SZ0142; 2018SZ0189
GroupedDBID	00X 0YH 53G AAKDD ABUPF ACGFS ADBBV ADCVX AENEX AIJEM ALMA_UNASSIGNED_HOLDINGS AOIJS AQTUD BABNJ BLEHA CCCUG DGEBU DGFLZ EBS EMOBN EUPTU GROUPED_DOAJ H13 HYE KRBQP KSSTO KTTOD KWAYT KYCEM LJTGL M4Z O9- OK1 RPM TDBHL TFL TFW 4.4 AAYXX CITATION DEAQA EJD OVD TEORI TNTFI TTHFI ACENM NPM 7X8 5PM
ID	FETCH-LOGICAL-c534t-bb5e5ab3b066f9f981a6fcf61ba7ffadae1064d49a6a496409a4417acc18f6de3
IEDL.DBID	TFW
ISICitedReferencesCount	38
ISICitedReferencesURI	http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000605327400001&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
ISSN	2162-402X 2162-4011
IngestDate	Fri Oct 03 12:52:51 EDT 2025 Tue Nov 04 02:02:28 EST 2025 Wed Oct 01 14:43:19 EDT 2025 Thu Jan 02 22:57:24 EST 2025 Tue Nov 18 21:10:09 EST 2025 Thu Nov 13 04:30:04 EST 2025 Fri Nov 07 04:29:39 EST 2025
IsDoiOpenAccess	true
IsOpenAccess	true
IsPeerReviewed	true
IsScholarly	true
Issue	1
Keywords	gastric cancer PD-L1/PD-1 blockades Tumor-associated macrophages
Language	English
License	open-access: http://creativecommons.org/licenses/by-nc/4.0/: This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (http://creativecommons.org/licenses/by-nc/4.0/), which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. 2020 The Author(s). Published with license by Taylor & Francis Group, LLC. This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (http://creativecommons.org/licenses/by-nc/4.0/), which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
LinkModel	DirectLink
MergedId	FETCHMERGED-LOGICAL-c534t-bb5e5ab3b066f9f981a6fcf61ba7ffadae1064d49a6a496409a4417acc18f6de3
Notes	ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 Rui Zhao, Qianyi Wan, and Yong Wang contributed equally to this study.
ORCID	0000-0002-3996-868X
OpenAccessLink	https://www.tandfonline.com/doi/abs/10.1080/2162402X.2020.1862520
PMID	33457080
PQID	2478771311
PQPubID	23479
ParticipantIDs	crossref_citationtrail_10_1080_2162402X_2020_1862520 crossref_primary_10_1080_2162402X_2020_1862520 pubmed_primary_33457080 doaj_primary_oai_doaj_org_article_0f3e3e38eed247ba9e180b265b3b9a95 proquest_miscellaneous_2478771311 informaworld_taylorfrancis_310_1080_2162402X_2020_1862520 pubmedcentral_primary_oai_pubmedcentral_nih_gov_7781754
PublicationCentury	2000
PublicationDate	2021-01-01
PublicationDateYYYYMMDD	2021-01-01
PublicationDate_xml	– month: 01 year: 2021 text: 2021-01-01 day: 01
PublicationDecade	2020
PublicationPlace	United States
PublicationPlace_xml	– name: United States
PublicationTitle	Oncoimmunology
PublicationTitleAlternate	Oncoimmunology
PublicationYear	2021
Publisher	Taylor & Francis Taylor & Francis Group
Publisher_xml	– name: Taylor & Francis – name: Taylor & Francis Group
References	e_1_3_10_27_1 e_1_3_10_26_1 e_1_3_10_25_1 e_1_3_10_24_1 e_1_3_10_46_1 e_1_3_10_47_1 e_1_3_10_29_1 e_1_3_10_28_1 e_1_3_10_4_1 e_1_3_10_30_1 e_1_3_10_5_1 e_1_3_10_2_1 e_1_3_10_3_1 e_1_3_10_8_1 e_1_3_10_11_1 e_1_3_10_34_1 e_1_3_10_9_1 e_1_3_10_12_1 e_1_3_10_33_1 e_1_3_10_6_1 e_1_3_10_32_1 e_1_3_10_7_1 e_1_3_10_10_1 e_1_3_10_31_1 e_1_3_10_15_1 e_1_3_10_38_1 e_1_3_10_16_1 e_1_3_10_37_1 e_1_3_10_13_1 e_1_3_10_36_1 e_1_3_10_14_1 e_1_3_10_35_1 e_1_3_10_19_1 e_1_3_10_17_1 e_1_3_10_18_1 e_1_3_10_39_1 e_1_3_10_41_1 e_1_3_10_40_1 e_1_3_10_43_1 e_1_3_10_44_1 e_1_3_10_45_1 e_1_3_10_23_1 e_1_3_10_22_1 e_1_3_10_21_1 e_1_3_10_20_1 e_1_3_10_42_1
References_xml	– ident: e_1_3_10_11_1 doi: 10.1093/annonc/mdz197 – ident: e_1_3_10_19_1 doi: 10.1186/s12885-018-4384-8 – ident: e_1_3_10_36_1 doi: 10.1038/s41568-019-0235-4 – ident: e_1_3_10_38_1 doi: 10.1016/j.immuni.2020.06.016 – ident: e_1_3_10_21_1 doi: 10.1200/JCO.2017.76.6212 – ident: e_1_3_10_29_1 doi: 10.1158/2326-6066.CIR-17-0746 – ident: e_1_3_10_24_1 doi: 10.1038/s41577-019-0127-6 – ident: e_1_3_10_31_1 doi: 10.1007/s10120-017-0760-3 – ident: e_1_3_10_4_1 doi: 10.1007/s10120-020-01090-4 – ident: e_1_3_10_42_1 doi: 10.1016/j.ccell.2018.02.005 – ident: e_1_3_10_20_1 doi: 10.1007/s10120-018-0903-1 – ident: e_1_3_10_13_1 doi: 10.1093/jnci/djaa051 – ident: e_1_3_10_22_1 doi: 10.1038/s41591-018-0101-z – ident: e_1_3_10_30_1 doi: 10.1038/s41467-018-03121-2 – ident: e_1_3_10_27_1 doi: 10.1038/nrclinonc.2016.217 – ident: e_1_3_10_2_1 doi: 10.3322/caac.21492 – ident: e_1_3_10_8_1 doi: 10.1080/2162402X.2019.1581547 – ident: e_1_3_10_26_1 doi: 10.1016/j.cmet.2019.06.001 – ident: e_1_3_10_17_1 doi: 10.1038/s41467-019-11788-4 – ident: e_1_3_10_32_1 doi: 10.1097/SLA.0000000000004037 – ident: e_1_3_10_14_1 doi: 10.1136/gutjnl-2015-310839 – ident: e_1_3_10_28_1 doi: 10.1016/j.cell.2010.03.014 – ident: e_1_3_10_3_1 doi: 10.2147/OTT.S246412 – ident: e_1_3_10_10_1 doi: 10.1186/s40425-019-0514-3 – ident: e_1_3_10_39_1 doi: 10.1016/j.ctrv.2017.11.007 – ident: e_1_3_10_33_1 doi: 10.1186/s13045-017-0408-0 – ident: e_1_3_10_37_1 doi: 10.1016/j.it.2019.02.003 – ident: e_1_3_10_25_1 doi: 10.1146/annurev-pathmechdis-012418-012718 – ident: e_1_3_10_5_1 doi: 10.1016/S1470-2045(16)00175-3 – ident: e_1_3_10_7_1 doi: 10.1093/annonc/mdy540 – ident: e_1_3_10_23_1 doi: 10.1007/s10120-019-00999-9 – ident: e_1_3_10_35_1 doi: 10.1038/nrd.2018.169 – ident: e_1_3_10_12_1 doi: 10.1038/nature13480 – ident: e_1_3_10_16_1 doi: 10.1001/jamaoncol.2018.0013 – ident: e_1_3_10_43_1 doi: 10.1111/cpr.12571 – ident: e_1_3_10_46_1 doi: 10.1158/2326-6066.CIR-19-0826 – ident: e_1_3_10_34_1 doi: 10.1016/j.ctrv.2020.102015 – ident: e_1_3_10_45_1 doi: 10.1038/s41467-017-01572-7 – ident: e_1_3_10_9_1 doi: 10.1038/s41591-018-0101-z – ident: e_1_3_10_41_1 doi: 10.1016/j.immuni.2019.04.010 – ident: e_1_3_10_44_1 doi: 10.1016/j.ccell.2018.03.008 – ident: e_1_3_10_18_1 doi: 10.1126/scitranslmed.3003689 – ident: e_1_3_10_15_1 doi: 10.1172/JCI91190 – ident: e_1_3_10_6_1 doi: 10.1007/s40265-020-01272-5 – ident: e_1_3_10_40_1 doi: 10.1038/ncomms8458 – ident: e_1_3_10_47_1 doi: 10.1038/s41586-020-2746-2
SSID	ssj0000605639
Score	2.4209557
Snippet	The efficacy of PD-1/PD-L1 blockades is heterogeneous in different molecular subtypes of gastric cancer (GC). In this study, we analyzed relevant clinical...
SourceID	doaj pubmedcentral proquest pubmed crossref informaworld
SourceType	Open Website Open Access Repository Aggregation Database Index Database Enrichment Source Publisher
StartPage	1862520
SubjectTerms	gastric cancer Original Research PD-L1/PD-1 blockades Tumor-associated macrophages
SummonAdditionalLinks	– databaseName: DOAJ Directory of Open Access Journals dbid: DOA link: http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1La9wwEBYltNBL6btu2qJCr-5asmxJx_QRekhCDlvYmxjJo3ZJ8BbvppB_n5HtXbyhsJdiMFi2ZUkz0sxI8vcx9inIIpCdMDnKGnJlvMwh6nSZuBjRKht7yPwzfXFhFgt7OaH6SnvCBnjgoeFmRSyRDkNjuVTag0VhCi_rypfegu3RSwttJ8HUMAaTYS_t9pcdU8ykqNNCwoJCQklJ5MhXieN7Yox6zP57iKX_8jvvb5-c2KPTp-zJ6Ejyk6ECz9gDbJ-zRwO15O0LNj8X-fXyCvn85HzNoUPeYdr0iw2n73Jy-zgm9AgIt3wV-eW3_EzM6Cy4J_N2BQ2u-bLlvyDxegQeknJ0L9nP0-_zrz_ykUEhD1WpNrn3FVZALUWORbTRGgF1DLEWHnSM0ABSRKgaZaEGZWuK9SBRkkEIwsS6wfIVO2pXLb5hvEmIhaoIooqVKqUHihtDTXkhCk9xUMbUtildGOHFE8vFtRMjCulWAi5JwI0SyNjn3Wt_BnyNQy98SXLaPZzgsfsEUho3Ko07pDQZs1Mpu00_OxIHKhNXHijAx61KOOqKaX0FWlzdrJ1MQEc64Rdl7PWgIrtilqWqNOWZMb2nPHv12L_TLn_3cN9aG_Lx1Nv_UfFj9limTTn9HNI7drTpbvA9exj-bpbr7kPfh-4Af60akQ priority: 102 providerName: Directory of Open Access Journals
Title	M1-like TAMs are required for the efficacy of PD-L1/PD-1 blockades in gastric cancer
URI	https://www.tandfonline.com/doi/abs/10.1080/2162402X.2020.1862520 https://www.ncbi.nlm.nih.gov/pubmed/33457080 https://www.proquest.com/docview/2478771311 https://pubmed.ncbi.nlm.nih.gov/PMC7781754 https://doaj.org/article/0f3e3e38eed247ba9e180b265b3b9a95
Volume	10
WOSCitedRecordID	wos000605327400001&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
hasFullText	1
inHoldings	1
isFullTextHit
isPrint
journalDatabaseRights	– providerCode: PRVAON databaseName: DOAJ Directory of Open Access Journals customDbUrl: eissn: 2162-402X dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0000605639 issn: 2162-402X databaseCode: DOA dateStart: 20200101 isFulltext: true titleUrlDefault: https://www.doaj.org/ providerName: Directory of Open Access Journals – providerCode: PRVAWR databaseName: Taylor & Francis Journals customDbUrl: eissn: 2162-402X dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0000605639 issn: 2162-402X databaseCode: TFW dateStart: 20180102 isFulltext: true titleUrlDefault: https://www.tandfonline.com providerName: Taylor & Francis – providerCode: PRVAWR databaseName: Taylor & Francis Journals customDbUrl: eissn: 2162-402X dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0000605639 issn: 2162-402X databaseCode: TFW dateStart: 20120101 isFulltext: true titleUrlDefault: https://www.tandfonline.com providerName: Taylor & Francis – providerCode: PRVAWR databaseName: Taylor & Francis Open Access customDbUrl: eissn: 2162-402X dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0000605639 issn: 2162-402X databaseCode: 0YH dateStart: 20200101 isFulltext: true titleUrlDefault: https://www.tandfonline.com providerName: Taylor & Francis
link	http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1La9wwEBZtaKGXvh_bx6JCr24sWbasY_pYckhCDlu6PYmRLCVLgrfYm0D-fWb8WLKhJYcWg8CyJfQYeb6Rxt8w9snL1KOeKJMgC0hU6WQCUdMtxWIMRpnYUeYf6KOjcrEwx4M3YTu4VZINHXuiiO5bTYsbXDt6xO1KUdCZwAKtO4lZiMlzSVY7Inty6pvPfm52WVJE66iDx193_lZ4Syl13P23mEv_hD9vu1He0EuzJ_-hR0_Z4wGU8r1eip6xe6F-zh72YSqvXrD5oUjOl2eBz_cOWw5N4E0gB-JQcWw7RwjJAzFRgL_iq8iPvyUHYhdTwR2qyjOoQsuXNT8BihHiuSdBa16yH7Pv86_7yRCNIfF5ptaJc3nIwWUOQUo00ZQCiuhjIRzoGKGCgNalqpSBApQp0G4ECm8G3osyFlXIXrGdelWHN4xXxH6oUi_ymKtMOkAb1BdYVwjCoU01YWqcDusHqnKKmHFuxcBoOg6YpQGzw4BN2OdNsd89V8ddBb7QXG9eJqrtLmPVnNhh5do0ZgGvEsGEVNqBCaJMnSxyHAoDJp8wc1NS7LrbaYl9WBSb3dGAj6NYWVzWdFYDdVhdtFYSaZImLqQJe92L2aaZWaZyjXVOmN4SwK1-bD-pl6cddbjWJeJF9fYf2vyOPZLk19NtQ71nO-vmInxgD_zletk2U3Y__bWPqV6U025_Y9otyGt_By1b
linkProvider	Taylor & Francis
linkToHtml	http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Lj9MwELbQAoIL70d4Golr2NixY_u4PFZFtBWHIpWTZTv2Uu0qRWkXaf89M0latSvQHkCRIsWJrbE9zjw8_oaQt4EXAeSEziOvXC6057lLCh8xF2M0wqQOMn-splM9n5vdszAYVok2dOqBIrp_NS5udEZvQuIOOatwU2AO5h2HIlDKJQez_brUSiOXF99HWz9LAfo6SOHN4Z2_1d4TSx16_yXs0j9poJcDKXck0_Hd_9Gne-TOoJfSo56R7pNrsXlAbvaZKi8ektmE5WeL00hnR5MVdW2kbcQY4lhTIJ6CFkkjglG4cEGXiX79mI_ZIdwZ9SAtT10dV3TR0BOHaUICDchr7SPy7fjT7MMoHxIy5EGWYp17L6N0vvSgpySTjGauSiFVzDuVkqtdBANT1MK4yglTgenoMMOZC4HpVNWxfEwOmmUTnxJaIwCiKAKTSYqSewdmaKigrRiZB7MqI2IzHzYMaOWYNOPMsgHUdDNgFgfMDgOWkXfbaj97uI6rKrzHyd5-jGjbXcGyPbHD4rVFKiNcGvQJLpR3JjJdeF5JGArjjMyI2WUVu-6cLanPjGLLKwh4s-ErCysbt2tcE5fnK8sRN0khHFJGnvR8tiWzLIVU0GZG1B4H7vVj_02z-NGhhyulQWUUz_6B5tfk1mg2Gdvx5-mX5-Q2xzCfziv1ghys2_P4ktwIv9aLVfuqW4u_AcVwLnM
linkToPdf	http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1La9wwEBYlfdBL3w_3qUKvbixZkq1j2nRp6WbZw5buTUiylC4J3mBvCvn3nfFjyYaWHFoMBsuWkMYjzzfS-BtC3nueebATZRq4sqkoHU9tLPASczEGLXTsKPOnxWxWLpd6PkQTtkNYJfrQsSeK6L7VOLnPqjhGxO1zpnBPYAneHYciwOSSg9d-E6CzRMVeTH5sl1kygOtghMd_d_5We8cqdeT9V6hL_wRAr8ZRXjJMk_v_YUgPyL0BldKDXo0ekhuhfkRu93kqLx6TxRFLT1cngS4Ojlpqm0CbgBHEoaLQdwoYkgakorD-gq4jnR-mU7YPZ0Yd2MoTW4WWrmp6bDFJiKceNa15Qr5PPi8-fUmHdAypl7nYpM7JIK3LHaCUqKMumVXRR8WcLWK0lQ3gXopKaKus0AocR4v5zaz3rIyqCvlTslev6_Cc0ArpD0XmmYxS5NxZcEK9grZCYA6cqoSI8XUYP3CVY8qMU8MGStNRYAYFZgaBJeTDttpZT9ZxXYWP-K63DyPXdlewbo7NMHVNFvMARwlogovCWR1YmTmuJIhCWy0Toi9ritl0Sy2xz4ti8ms68G5UKwPzGjdrbB3W563hyJpUIBlSQp71arbtZp4LWUCbCSl2FHBnHLt36tXPjju8KEoAjOLFP_T5LbkzP5yY6dfZt5fkLscYn25J6hXZ2zTn4TW55X9tVm3zppuJvwFsvi1h
openUrl	ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=M1-like+TAMs+are+required+for+the+efficacy+of+PD-L1%2FPD-1+blockades+in+gastric+cancer&rft.jtitle=Oncoimmunology&rft.au=Zhao%2C+Rui&rft.au=Wan%2C+Qianyi&rft.au=Wang%2C+Yong&rft.au=Wu%2C+Yutao&rft.date=2021-01-01&rft.pub=Taylor+%26+Francis&rft.issn=2162-4011&rft.eissn=2162-402X&rft.volume=10&rft.issue=1&rft_id=info:doi/10.1080%2F2162402X.2020.1862520&rft_id=info%3Apmid%2F33457080&rft.externalDocID=PMC7781754
thumbnail_l	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2162-402X&client=summon
thumbnail_m	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2162-402X&client=summon
thumbnail_s	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2162-402X&client=summon